Compounds > men 11558
Page last updated: 2024-11-11

men 11558

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9829402
CHEMBL ID435324
MeSH IDM0436429

Synonyms (3)

Synonym
CHEMBL435324 ,
men-11558
bdbm50404020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-K receptorHomo sapiens (human)Ki0.00200.00011.92429.7930AID211887; AID211890; AID211891; AID211892; AID282615
Substance-P receptorCavia porcellus (domestic guinea pig)Ki0.00200.00130.69133.4000AID282615
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-K receptorOryctolagus cuniculus (rabbit)Kd0.00500.00500.00500.0050AID145623
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)KD/Ki0.01260.00740.02000.0400AID68771
Substance-K receptorHomo sapiens (human)KD/Ki0.49270.00040.03491.0700AID163136; AID163138; AID202474; AID202475; AID202476; AID217944; AID219264; AID219265; AID219266; AID219919; AID219920; AID219925; AID219926; AID219929; AID219932; AID219934; AID219935; AID43022; AID68754; AID68756; AID68771; AID80500; AID93319
Histamine H2 receptorCavia porcellus (domestic guinea pig)KD/Ki0.08000.01150.04570.0800AID80500
E-selectinRattus norvegicus (Norway rat)KD/Ki0.00350.00150.00250.0035AID202476
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (49)

Assay IDTitleYearJournalArticle
AID219920Binding affinity against Y169A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID68754Binding affinity against F112A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID282617Antagonist activity at NK2 receptor in rat urinary bladder assessed as effect on beta-Ala8]NKA(4-10)-induced mechanical activity2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.
AID163136Binding affinity against Q109A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID145623In vitro functional activity towards Neurokinin NK2 receptor on isolated rabbit urinary bladder (RUB)2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: new antagonists for the human tachykinin NK-2 receptor.
AID219266Binding affinity against wild-type human Wild-type tachykinin receptor 2 (hNK-2R) using [3H]-SR-48,968 as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219932Binding affinity against Y269F human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID43023Binding affinity against C167A human neurokinin-2 receptor (hNK-2R) using [3H]-nepadutant as a radioligand; ND is No Data2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219267Compound was evaluated for Kd value against [125I]NKA on the Wild-type tachykinin receptor 22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID43022Binding affinity against C167A human neurokinin-2 receptor (hNK-2R) using [3H]SR-48,968 as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211892Displacement of [125I]NKA from human Tachykinin receptor 2 expressed in CHO cells2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Insertion of 2-carboxysuccinate and tricarballylic acid fragments into cyclic-pseudopeptides: new antagonists for the human tachykinin NK-2 receptor.
AID212221Base dissociation constant measured against Tachykinin receptor 32000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID68771Binding affinity against F293A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID141382Compound was evaluated for Kd value against [3H]-SR- 48968 on the Tyr206Phe mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID208250Base dissociation constant measured against Tachykinin receptor 12000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID219265Binding affinity against wild-type human Wild-type tachykinin receptor 2 (hNK-2R) using [125I]-NKA as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID202474Binding affinity against S164A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID208387Binding affinity against T171A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand; ND is No Data2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID141379Compound was evaluated for Kd value against [125I]NKA on the Tyr266Phe mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID219927Binding affinity against Y266F human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand; ND is No Data2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID80500Binding affinity against H198A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211508Base dissociation constant measured against Tachykinin receptor 22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID217944Binding affinity against W263A human neurokinin-2 receptor (hNK-2R) using [3H]SR-48,968 as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID202476Binding affinity against S170A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211890Compound was tested for it's binding affinity against human Tachykinin receptor 22002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Successful bridging from a peptide to a non peptide antagonist at the human tachykinin NK-2 receptor.
AID68756Binding affinity against F168A human neurokinin-2 receptor (hNK-2R) using [3H]-nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219268Compound was evaluated for Kd value against [3H]-SR- 48968 on the Wild-type tachykinin receptor 22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID219926Binding affinity against Y266F human neurokinin-2 receptor (hNK-2R) using [125I]NKA as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID163138Binding affinity against Q166A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211891Binding affinity towards Tachykinin receptor 22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID144211Binding affinity against N110A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand; ND is No Data2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219264Binding affinity against wild type human Wild-type tachykinin receptor 2 (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211887Inhibitory affinity constant (pKi) against tachykinin receptor 2 (NK-2R) using heterologous competition experiments2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219925Binding affinity against Y206F human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID141381Compound was evaluated for Kd value against [3H]-SR- 48968 on the Tyr206Ala mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID141380Compound was evaluated for Kd value against [3H]-SR- 48968 on the Phe270Ala mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID282615Displacement of [125I]neurokinin A from human NK2 receptor expressed in CHOK1 cells2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.
AID141378Compound was evaluated for Kd value against [125I]NKA on the Tyr206Phe mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID211886In Vitro evaluation for the functional activity towards Tachykinin receptor 22000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID219919Binding affinity against Y107A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID202475Binding affinity against S170A human neurokinin-2 receptor (hNK-2R) using [125I]NKA as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219935Binding affinity against Y289T human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID93319Binding affinity against I202F human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID141383Compound was evaluated for Kd value against [3H]-SR- 48968 on the Tyr266Phe mutated human NK-2 receptor2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists.
AID219934Binding affinity against Y289F human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID217945Binding affinity against W263A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand; ND is No Data2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID219929Binding affinity against Y269A human neurokinin-2 receptor (hNK-2R) using [3H]nepadutant as a radioligand2002Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies.
AID211883Functional affinity was evaluated by measuring the intracellular calcium concentration in CHO cells transfected with the human Tachykinin receptor 2 using Fura-2; NA denotes not available2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Successful bridging from a peptide to a non peptide antagonist at the human tachykinin NK-2 receptor.
AID282616Antagonist activity at NK2 receptor in rabbit pulmonary artery assessed as effect on neurokinin A-induced mechanical activity2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.03 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
neurokinin a
Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.		2.0110
men 11420
[no description available]		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials